Investigating Biosimilar Use in Oncology From 2019 to 2021
In a recent publication in the Journal of Clinical Oncology, researchers sought to investigate the correlation of time, practice type, and payment source with regard to the use of oncology biosimilars in the United States from 2019 to 2021. The researchers obtained biologic utilization data from 38 practices and focused on data from specific originator biologics commonly prescribed in oncology practice. Read more.

Comparing Monoclonal Antibody Biosimilars With Marketed Biologics
In a recent publication in Expert Opinion on Biological Therapy, researchers examined adverse event reporting patterns for monoclonal antibody (mAb) biosimilars in the United States compared with their originator/reference biologics. They also examined disproportionate reporting signals for these mAb biosimilars, defined as a statistical association between a medication and adverse events. Learn more about the study results.

Study Explores Cost Effectiveness of Trastuzumab Biosimilars
In a recent publication in Journal of Clinical Oncology, researchers conducted a study to evaluate trastuzumab to identify how trends in the price and treatment cost of the originator brand and biosimilar forms have changed since the availability of the biosimilar for the treatment of human epidermal growth factor receptor 2–positive breast cancer. Read more.